We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+43.68%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$1.35B
AUM Growth
+$397M
Cap. Flow
+$127M
Cap. Flow %
9.41%
Top 10 Hldgs %
60.29%
Holding
72
New
21
Increased
13
Reduced
7
Closed
23

Top Buys

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$84.3M
2
XNCR icon
Xencor
XNCR
+$62.7M
3
RNAM
Avidity Biosciences
RNAM
+$60.7M
4
AKUS
Akouos Inc
AKUS
+$44M
5
RCUS icon
Arcus Biosciences
RCUS
+$41M

Top Sells

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$61.6M
2
FATE icon
Fate Therapeutics
FATE
+$51.3M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$45M
4
KYNB
Kyntra Bio
KYNB
+$30.7M
5
IPHA
Innate Pharma
IPHA
+$29.8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
51
DELISTED
Blueprint Medicines
BPMC
– –
-13,946
Closed -$816K
CRSP icon
52
CRISPR Therapeutics
CRSP
$4.55B
– –
-30,510
Closed -$1.29M
CTMX icon
53
CytomX Therapeutics
CTMX
$686M
– –
-1,101
Closed -$8K
EXEL icon
54
Exelixis
EXEL
$13.9B
– –
-6,269
Closed -$108K
KYNB
55
Kyntra Bio
KYNB
$28.7M
– –
-35,286
Closed -$30.7M
FOLD
56
DELISTED
Amicus Therapeutics
FOLD
– –
-1,249,611
Closed -$11.5M
GMAB icon
57
Genmab
GMAB
$17.8B
– –
-653,981
Closed -$13.9M
IONS icon
58
Ionis Pharmaceuticals
IONS
$9.05B
– –
-208,609
Closed -$9.86M
IPHA
59
Innate Pharma
IPHA
$179M
– –
-4,465,668
Closed -$29.8M
IRWD icon
60
Ironwood Pharmaceuticals
IRWD
$630M
– –
-4,393,236
Closed -$45M
MRUS
61
DELISTED
Merus
MRUS
– –
-1,715,962
Closed -$20.8M
PBYI icon
62
Puma Biotechnology
PBYI
$399M
– –
-2,536,156
Closed -$21.4M
RGLS
63
DELISTED
Regulus Therapeutics
RGLS
– –
-188,681
Closed -$870K
RNAC icon
64
Cartesian Therapeutics
RNAC
$221M
– –
-153,257
Closed -$11.1M
SGMO
65
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-2,308,079
Closed -$14.7M
TCRT icon
66
Alaunos Therapeutics
TCRT
$4.64M
– –
-25,000
Closed -$9.19M
VIR icon
67
Vir Biotechnology
VIR
$1.45B
– –
-270,418
Closed -$9.27M
VSTM icon
68
Verastem
VSTM
$532M
– –
-271,318
Closed -$8.6M
ZYME icon
69
Zymeworks
ZYME
$1.65B
– –
-41,407
Closed -$1.47M
PVLA
70
Palvella Therapeutics
PVLA
$1.98B
– –
-3,302
Closed -$602K
TRIL
71
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-291,997
Closed -$1.18M
CHMA
72
DELISTED
Chiasma, Inc. Common Stock
CHMA
– –
-1,512,627
Closed -$5.52M
1 2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q2 2020 Portfolio in Review

As of Q2 2020, EcoR1 Capital held 72 positions worth $1.35B, up 41% from $957M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

EcoR1 Capital deployed $127M of net new capital in Q2 2020, opening 21 new positions and adding to 13 existing holdings. Its largest new stake was Oric Pharmaceuticals: 2,642,218 shares worth $89.1M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was Fate Therapeutics, an estimated $51.3M trimmed.

  • EcoR1 Capital's largest Q2 2020 buy was Oric Pharmaceuticals: 2,642,218 shares worth $89.1M.
  • EcoR1 Capital added most to Xencor in Q2 2020, an estimated $62.7M increase.
  • EcoR1 Capital's biggest Q2 2020 reduction was Fate Therapeutics, cutting an estimated $51.3M.
  • EcoR1 Capital fully exited Arvinas in Q2 2020, selling an estimated $61.6M.
  • EcoR1 Capital's ten largest holdings make up 60% of its $1.35B portfolio in Q2 2020.
  • EcoR1 Capital opened 21 new positions and closed 23 in Q2 2020.
  • EcoR1 Capital's portfolio value rose 41% quarter-over-quarter to $1.35B.

Based on EcoR1 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.